Italia markets closed

Ambu A/S (0MJF.L)

LSE - LSE Prezzo differito. Valuta in DKK.
Aggiungi a watchlist
77,70+2,01 (+2,65%)
Alla chiusura: 06:18PM BST
Schermo intero
Chiusura precedente75,69
Aperto75,64
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno75,60 - 79,74
Intervallo di 52 settimane75,60 - 79,74
Volume32.810
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)0,54
Rapporto PE (ttm)0,77
EPS (ttm)1,01
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Ambu A/S: Financial Calendar

    This financial calendar lists the expected dates of publication of financial announcements and the Annual General Meeting for the financial year 2022/23. Please see attached PDF. CONTACTS Thomas Frederik Schmidt Chief Financial Officer tfsc@ambu.com / +45 2084 0500Nicolai Thomsen Director, Investor Relations & Strategic Financial Planning nith@ambu.com / +45 2620 8047 Attachment Financial calendar_Company_Announcement_2021_22_no_14

  • GlobeNewswire

    Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities

    Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached documents discloses the data of the transactions made in Ambu shares. Attachment 29_08_2022 Britt Meelby Jensen

  • GlobeNewswire

    INTERIM REPORT FOR Q3 2021/22

    Ambu delivered 8% organic revenue growth in Q3 with 5% organic growth year-to-date. This was driven by a continued rapid uptake of Ambu’s single-use endoscopes within urology and ENT, as well as pent-up demand for Anaesthesia and Patient Monitoring & Diagnostics (PMD) products. The financial outlook from 3 August, 2022 is maintained. Britt Meelby Jensen, Chief Executive Officer of Ambu, says:“For Q3, I am happy to see that we continued to deliver rapid growth in our urology and ENT businesses, w